Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 2/20 | 0.42 |
| ▸ | SCN4A | P35499 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996836 | 0.83 | SLC6A4 (0.56) | TAAR1SLC6A4CYP2D6 | |
| SCHEMBL6636645 | 0.78 | CSNK1E (0.44) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| L-Phenylalaninol SCHEMBL9733120 | 0.73 | EPHX1 (0.64) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL4950924 | 0.72 | EPHX1 (0.62) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL1056062 | 0.72 | EPHX1 (0.62) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL4950704 | 0.72 | EPHX1 (0.62) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL479459 | 0.72 | EPHX1 (0.62) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL1695172 | 0.72 | SLC1A3 (0.49) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2488884 | 0.72 | SLC6A2 (0.52) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| L-Phenylalaninol SCHEMBL5967085 | 0.72 | EPHX1 (0.61) | EPHX1SLC6A2TAAR1MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3116897-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| EP-3414247-B1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-2068878-B1 | RHO KINASE INHIBITORS | AERIE PHARMACEUTICALS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3414247-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-19 | — | — | EP | disclosed |
| WO-2005026154-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026165-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| US-6861529-B2 | Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors | PFIZER INC (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20050026917-A1 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| EP-1404316-A1 | CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003004018-A1 | CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| US-6107321-A | Diazabicyclooctane derivatives having selective 5-HT1Dalpha agonist activity | MERCK SHARP & DOHME LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| WO-1997011945-A1 | DIAZABICYCLOOCTANE DERIVATIVES HAVING SELECTIVE 5-HT1DALPHA ANTAGONIST ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | EPHX1 4404/4885SLC6A2 4688/4885TAAR1 1824/4885 |
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | GABARAP, GABRA3, GABRA2 | EPHX1 1528/4885SLC6A2 725/4885TAAR1 97/4885 |
| US-20050026917-A1 | Tricyclic indanyls as integrin inhibitors | ITGB1, ILK, ITGB2 | EPHX1 1714/4885SLC6A2 4733/4885TAAR1 4127/4885 |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | EPHX1 4025/4885SLC6A2 4595/4885TAAR1 2467/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | EPHX1 832/4885SLC6A2 3676/4885TAAR1 4563/4885 |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | EPHX1 4025/4885SLC6A2 4595/4885TAAR1 2467/4885 |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | EPHX1 4492/4885SLC6A2 4691/4885TAAR1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.